Aurora Biolabs

Executive Summary

Aurora Biolabs is a San Diego-based private company specializing in the manufacture of premium recombinant proteins and TR-FRET fluorescence inhibitor assays for drug discovery and optimization. Founded in 2015 and located in the Sorrento Valley biotech hub, the company serves as a critical supplier to pharmaceutical and biotechnology research organizations, enabling high-throughput screening and lead optimization. Its focus on TR-FRET technology positions it within the growing proteomics and diagnostics sectors, where sensitive and robust assay systems are in high demand for target validation and compound profiling. Despite limited public information on funding or revenue, Aurora Biolabs has established itself as a reliable service provider in a niche but essential market. The company’s value proposition lies in its ability to deliver custom recombinant proteins and ready-to-use assay kits that accelerate early-stage drug discovery. With the increasing emphasis on targeted therapies and precision medicine, Aurora is well-positioned to benefit from sustained R&D investment. However, its growth trajectory remains constrained by its private status and lack of disclosed partnerships or product pipeline. Future success will likely hinge on expanding its catalog, forging strategic collaborations, and potentially attracting acquisition interest from larger life science tools companies.

Upcoming Catalysts (preview)

• Q4 2026Launch of new TR-FRET assay panel for oncology targets70% success
• Q1 2027Strategic partnership with a mid-tier pharma company50% success
• Q3 2026Expansion of custom recombinant protein catalog80% success